Open AccessVaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines
Author(s) -
Trotter Caroline L.,
Ramsay Mary E.
Publication year - 2007
Publication title -
fems microbiology reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.91
H-Index - 212
eISSN - 1574-6976
pISSN - 0168-6445
DOI - 10.1111/j.1574-6976.2006.00053.x
Subject(s) - meningococcal disease , vaccination , conjugate , conjugate vaccine , medicine , meningococcal vaccine , immunization , neisseria meningitidis , virology , incidence (geometry) , disease , immunology , biology , antigen , mathematical analysis , physics , mathematics , bacteria , optics , genetics
At the end of 2005, six European countries had implemented public immunization campaigns with serogroup C conjugate vaccines, and all had experienced substantial declines in the incidence of serogroup C disease. A quadrivalent ACWY meningococcal vaccine is in use in the USA, but serogroup A is extremely rare in Europe and serogroups Y and W135 are infrequent causes of disease. This paper outlines recommendations on the use of conjugate vaccines in Europe based on the experience with meningococcal C conjugate (MCC) vaccines so far.